共 50 条
Patient-Led Urate Self-Monitoring to Improve Clinical Outcomes in People With Gout: A Feasibility Study
被引:2
作者:
Michael, Toni J. F.
[1
]
Wright, Daniel F. B.
[2
]
Chan, Jian S.
[3
]
Coleshill, Matthew J.
[4
]
Aslani, Parisa
[1
]
Hughes, Dyfrig A.
[5
]
Day, Richard O.
[3
,6
]
Stocker, Sophie L.
[1
,6
]
机构:
[1] Univ Sydney, Fac Med & Hlth, Sch Pharm, Camperdown, Australia
[2] Univ Otago, Sch Pharm, Dunedin, New Zealand
[3] Univ New South Wales, Fac Med, St Vincents Clin Campus, Sydney, Australia
[4] Univ New South Wales, Black Dog Inst, Fac Med, Randwick, Australia
[5] Bangor Univ, Sch Med & Hlth Sci, Bangor, Wales
[6] St Vincents Hosp, Dept Clin Pharmacol & Toxicol, Darlinghurst, Australia
关键词:
MEDICATION ADHERENCE;
BLOOD-PRESSURE;
MANAGEMENT;
REGRESSION;
DISEASE;
CARE;
D O I:
10.1002/acr2.11666
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
ObjectiveSelf-monitored point-of-care urate-measuring devices are an underexplored strategy to improve adherence to urate-lowering therapy and clinical outcomes in gout. This study observed patient-led urate self-monitoring practice and assessed its influence on allopurinol adherence, urate control, and health-related quality of life. MethodsPeople with gout (n = 31) and prescribed allopurinol self-monitored their urate concentrations (HumaSens2.0(plus)) at baseline and thereafter monthly for 12 months (3 months per quarter). Adherence to allopurinol was measured using medication event monitoring technology (Medication Event Monitoring System cap). Time spent below the target urate concentration (<0.36 mmol/L) was determined. Health-related quality of life was measured using a survey (EuroQoL EQ-5D-5L). Gout flares were recorded. Two-tailed Spearman correlation and the Wilcoxon matched-pairs signed-rank test (P < 0.05) were used for statistical comparisons. ResultsMost participants were male (94%) and had urate concentrations below the target (74%) at baseline. Overall, seven participants demonstrated repeated periods of "missed doses" (two or fewer allopurinol doses missed consecutively) and "drug holidays" (three or more missed doses). Most participants (94%) persisted with allopurinol. Time spent within the target urate concentration increased 1.3-fold (from 79% to 100%; P = 0.346), and the incidence of gout flares decreased 1.6-fold (from 8 to 5; P = 0.25) in the final quarter compared to that in the first quarter of the study. Health-related quality of life was reduced for participants reporting at least one gout flare (median utility values 0.9309 vs 0.9563, P = 0.04). ConclusionPatient-led urate self-monitoring may support the maintenance of allopurinol adherence and improve urate control, thus reducing the incidence of gout flares. Further research on patient-led urate self-monitoring in a randomized controlled study is warranted.
引用
收藏
页码:403 / 411
页数:9
相关论文